Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow, ...

Earlier studies often prioritized one scale at the expense of the other and, because this, missed critical connections. In pulmonary hypertension, however, this partnership turns lethal. PAAFs start ...

Harnessing CT data to quantify cardiac and vascular structures has the potential to improve the diagnosis of heart failure and pulmonary hypertension (PH). This study aims to develop an automated deep ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

"Pulmonary hypertension usually affects people aged 30 to 60. Its early signs and symptoms can mimic those of various other medical conditions, making early detection challenging," explains Dr Garde.

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow ...

On May 5, more than 80 organizations around the world will join to raise awareness of pulmonary hypertension (PH), a serious but often under-recognized cardiovascular disease affecting more than 75 ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.